AIP
CLDX icon

Ameritas Investment Partners’s Celldex Therapeutics CLDX Stock Holding History

Ameritas Investment Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Hold
5,472
– – 0.01% 1348
2025
Q4 		$149K Hold
5,472
– – ﹤0.01% 1447
2025
Q3 		$142K Sell
5,472
-1,072
-16% -$24.8K ﹤0.01% 1462
2025
Q2 		$133K Hold
6,544
– – ﹤0.01% 1561
2025
Q1 		$119K Hold
6,544
– – ﹤0.01% 1584
2024
Q4 		$165K Hold
6,544
– – 0.01% 1434
2024
Q3 		$222K Buy
6,544
+346
+6% +$13.2K 0.01% 1249
2024
Q2 		$229K Hold
6,198
– – 0.01% 1174
2024
Q1 		$260K Buy
6,198
+1,582
+34% +$65K 0.01% 1122
2023
Q4 		$183K Hold
4,616
– – 0.01% 1320
2023
Q3 		$127K Buy
4,616
+779
+20% +$24.4K 0.01% 1488
2023
Q2 		$130K Buy
3,837
+312
+9% +$10.5K ﹤0.01% 1408
2023
Q1 		$127K Hold
3,525
– – 0.01% 1373
2022
Q4 		$164K Hold
3,525
– – 0.01% 1267
2022
Q3 		$99K Hold
3,525
– – ﹤0.01% 1493
2022
Q2 		$95K Hold
3,525
– – ﹤0.01% 1544
2022
Q1 		$120K Hold
3,525
– – ﹤0.01% 1511
2021
Q4 		$136K Hold
3,525
– – ﹤0.01% 1498
2021
Q3 		$190K Buy
3,525
+451
+15% +$21.2K 0.01% 1237
2021
Q2 		$103K Buy
+3,074
New +$84.4K ﹤0.01% 1705
2018
Q2 		– Sell
-690
Closed -$24K – 3008
2018
Q1 		$24K Hold
690
– – ﹤0.01% 2319
2017
Q4 		$29K Buy
690
+183
+36% +$7.84K ﹤0.01% 2237
2017
Q3 		$18K Hold
507
– – ﹤0.01% 2474
2017
Q2 		$19K Hold
507
– – ﹤0.01% 2478
2017
Q1 		$27K Buy
+507
New +$26.4K ﹤0.01% 2225
2015
Q2 		– Sell
-524
Closed -$219K – 1173
2015
Q1 		$219K Buy
+524
New +$187K 0.01% 972
2013
Q4 		– Sell
-477
Closed -$253K – 1065
2013
Q3 		$253K Buy
+477
New +$164K 0.02% 826

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Ameritas Investment Partners's CLDX Position: Q1 2026 in Review

Ameritas Investment Partners held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 5,472 shares worth $174K. The position accounts for 0.01% of the portfolio, ranked #1348.

Ameritas Investment Partners first reported a position in CLDX in Q3 2013 and has held it in 27 quarters since. The position peaked at $260K in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Ameritas Investment Partners held 5,472 shares of Celldex Therapeutics worth $174K as of Q1 2026.
  • Ameritas Investment Partners left its Celldex Therapeutics share count unchanged in Q1 2026.
  • Celldex Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1348 holding.
  • Ameritas Investment Partners first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 27 quarters since.
  • Ameritas Investment Partners's Celldex Therapeutics position peaked at $260K in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.